Generic Drug Cos. Invoke FTC Restitution Limits Against AGs
Law360 (May 6, 2021, 7:41 PM EDT) -- The potential influence of the U.S. Supreme Court decision striking down the Federal Trade Commission's claimed authority to recover ill-gotten gains in federal court continues to spread, with generic-drug makers citing the ruling Wednesday to fight state attorneys general's price-fixing claims in sprawling Pennsylvania federal court litigation.
The justices' unanimous decision in AMG Capital v. FTC bolsters arguments that the state enforcers, suing alongside a host of private plaintiffs in the multidistrict litigation, cannot pursue financial penalties, the generic-drug makers said in notices supplementing their motions to dismiss two of the attorneys general's three complaints.
The April 22 high court decision has already been...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!